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Abstract 
Background: Cardiovascular (CV) disease due to atherosclerosis is a major cause of morbidity and mortality in adult 
patients with diabetes, either type 1 or type 2 diabetes. The aim of the study was to assess the association of the fre‑
quency and the burden of subclinical carotid atherosclerotic disease in patients with type 1 diabetes according to the 
presence and severity of diabetic retinopathy (DR).
Methods: A cross‑sectional study was conducted in 340 patients with type 1 diabetes (41.5% with DR), and in 
304 non‑diabetic individuals. All participants were free from previous CV disease and chronic kidney disease (CKD). 
B‑mode carotid ultrasound imaging was performed in all the study subjects. Patients with type 1 diabetes underwent 
a full eye examination, and DR patients were divided into two groups: mild disease and advanced disease.
Results: In the group of patients with type 1 diabetes, the percentage of patients with carotid plaques was higher in 
those with DR compared with those without DR (44.7% vs. 24.1%, p < 0.001). Patients with DR also presented a higher 
incidence of ≥ 2 carotid plaques (25.5% vs. 11.1%, p < 0.001). Apart from other traditional cardiovascular risk factors, 
the presence of advanced stages of DR was independently associated with the presence (p = 0.044) and the burden 
(≥ 2 carotid plaques; p = 0.009) of subclinical carotid atherosclerosis.
Conclusions: In patients with type 1 diabetes without previous CV disease or established CKD, the presence of 
advanced stages of DR is associated with a higher atherosclerotic burden in the carotid arteries. The presence of DR 
identifies patients at risk for carotid atherosclerotic disease.
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Background
Cardiovascular (CV) disease due to atherosclerosis is a 
major cause of morbidity and mortality in adult patients 
with diabetes, either type 1 or type 2 diabetes. Among the 
risk factors associated with the excess of cardiovascular 
risk in patients with type 1 diabetes are age, proteinuria, 
decreased glomerular filtration rate, hypertension, obe-
sity, poor glycemic control, lipid levels, smoking and dia-
betes duration [1]. Even in patients with optimal glycemic 
control, the risk of death from CV causes is still more 
than twice that of non-diabetic individuals [2]. Unlike 
patients with type 2 diabetes, those with type 1 diabetes 
generally do not have excess rates of obesity, hyperten-
sion, or hypercholesterolemia compared with the gen-
eral population [3]. Thus, the underlying mechanisms 
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responsible for the increased risk of death from any cause 
and of death from CV causes among patients with type 
1 diabetes who have good glycemic control are not fully 
understood. In recent years, a current line of thought has 
been that there is a “common soil” for the development 
of micro- and macrovascular complications of diabetes 
associated with common pathogenic pathways in both 
types of complications [4]. Diabetic retinopathy (DR) is a 
common and specific microvascular complication of dia-
betes that is identified in one-third of people with type 1 
diabetes [5]. Glycemic control is the main factor involved 
in appearance and progression of DR in these patients. 
Interestingly, the presence of morphological abnor-
malities in retinal microvasculature is even observed in 
childhood type 1 diabetic patients with short-term poor 
glycemic control [6].
It has been shown in several studies that DR is an inde-
pendent predictor of CV events and all-cause mortal-
ity in both patients with type 1 and type 2 diabetes [7]. 
Multiple potential mechanisms have been suggested to 
be involved in the pathophysiological link between dia-
betic micro- and macroangiopathy. These include oxida-
tive and glycemic stress, chronic low-grade inflammation 
and impaired vascular tissue repair mechanisms [4]. 
More recently, diabetic microangiopathy of the artery 
wall microvessels, named vasa vasorum, has also been 
reported in patients with type 2 diabetes [8]. It is inter-
esting to note that the main stimuli that drive diabetic 
microangiopathy angiogenesis are hypoxia and ischemia 
similar to what has been described in the retinal vascular 
changes that occur in DR [5]. Interestingly, the severity 
of retinopathy has been shown to be associated with the 
risk of incidental CV events in patients with type 2 diabe-
tes in the action to control cardiovascular risk in diabetes 
(ACCORD) eye study, as this risk increased from 1.5 in 
people with mild nonproliferative retinopathy to 2.4 in 
people with severe retinopathy [9]. In patients with type 
1 diabetes asymptomatic for coronary artery disease, 
severe forms of DR have been reported to be associated 
with the presence of coronary artery calcification [10], 
and also with increased carotid intima-media thickness 
[11].
On the other hand, established chronic kidney disease 
(CKD) is one of the main drivers of increased CV mor-
bidity and mortality in patients with type 1 diabetes. Spe-
cifically, in patients with type 1 diabetes, the presence of 
albuminuric [12] and nonalbuminuric [13] CKD is asso-
ciated with a higher risk of CV disease. In previous stud-
ies showing an increased CV risk in patients with DR, 
the inclusion of patients with CKD may have influenced 
the findings as DR is usually closely associated with dia-
betic nephropathy. Therefore, any studies considering the 
association of DR with CV disease should take this issue 
into consideration.
Carotid intima-media thickness (IMT) and the pres-
ence of carotid plaques are considered to be surrogate 
measures of atherosclerosis [14]. Both conditions are 
associated with CV risk factors [15], predict CV events 
independently of risk factors [16], and help to stratify 
patients into different risk categories [17]. However, it 
should be mentioned that the presence [18] and burden 
[19] of atherosclerotic plaque is a more powerful predic-
tor of CV risk compared with IMT alone.
Both IMT and the frequency of plaques have been 
reported to be increased in children, adolescents and 
adults with type 1 diabetes compared with age- and 
sex-matched healthy control subjects [1], although data 
regarding atherosclerotic plaques in patients with type 
1 diabetes are very scarce. A paucity of data exists on 
whether DR and subclinical atherosclerotic disease in the 
carotid artery territory in patients with type 1 diabetes 
are associated. Carotid plaque is recognized as an inde-
pendent risk factor for ischemic stroke [20] with a risk 
that is markedly increased both in patients with type 1 
and type 2 diabetes [21]. In patients with type 1 diabe-
tes, this risk has been described to be associated with 
the presence of diabetic nephropathy and severe diabetic 
retinopathy [22]. In patients with type 2 diabetes, ours 
and other groups have previously described that DR is an 
independent risk factor associated with the presence of 
carotid plaques in subjects without previous CV disease 
[23, 24]. In these patients, it has recently been described 
that carotid atherosclerosis is also an independent risk 
factor for stroke [25].
Therefore, we hypothesized that DR is associated with 
the presence of carotid plaques in subjects with type 1 
diabetes without previous CV disease and established 
chronic kidney disease. In the present study, we sought 
to assess the association of the frequency and burden 
of subclinical carotid atherosclerotic disease in patients 
with type 1 diabetes according to presence and severity of 
DR. As a secondary outcome, we also evaluated the dif-
ferences in the presence and burden of subclinical carotid 
atherosclerosis compared with non-diabetic subjects.
Methods
Subjects
This study was designed as a cross-sectional study in 
subjects with type 1 diabetes recruited from the dia-
betic outpatient clinics at two university hospitals in the 
North-Western region of Spain (Catalonia). All potential 
participants were identified from the electronic clini-
cal records from the two participating institutions that 
belong to the same health care organization.
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The inclusion criteria for type 1 diabetic subjects were 
as follows: age > 18 years; diabetes for at least 1 year; nor-
mal renal function [estimated glomerular filtration rate 
(eGFR > 60  mL/min)]; no previous cardiovascular (CV) 
disease defined as any form of clinical coronary heart 
disease, stroke or peripheral vascular disease; and any 
form of diabetic foot disease. We excluded patients with 
a urine albumin excretion ratio > 300 mg/g and any con-
ditions that precluded a proper full eye examination. A 
subject was considered to have previous hypertension 
or dyslipidaemia if he/she was taking medication for the 
given condition. The selection of non-diabetic control 
participants was based on the same criteria, except for 
the criteria that concerned the diabetic specific micro-
vascular complications (retinopathy and albuminuria). 
Additionally, subjects in the control group had fasting 
glucose and HbA1c values below 100  mg/dL and 5.7% 
HbA1c, respectively.
Clinical assessment
For each subject, the age, sex, weight, height, body mass 
index and waist circumference were obtained by stand-
ardized methods. Serum and spot urine samples were 
collected in the fasting state, and all serum and urine 
tests were performed using standard laboratory methods 
as previously described [23].
Ophthalmic examination
In subjects with type 1 diabetes, an experienced oph-
thalmologist performed a complete eye evaluation and 
defined DR according to the ETDRS classification in 
five stages: (1) no apparent retinopathy, (2) mild non-
proliferative retinopathy (NPDR) (defined by the pres-
ence of microaneurysms), (3) moderate NPDR (presence 
of microaneurysms, intraretinal hemorrhages or venous 
beading that did not reach the severity of the next stage), 
(4) severe NPDR (more than 20 intraretinal hemorrhages 
in four quadrants, venous beading in two quadrants or 
intraretinal microvascular abnormalities in one quad-
rant), and (5) proliferative diabetic retinopathy (PRD) 
defined by the presence of disc/retina/angle/iris neovas-
cularization, vitreous hemorrhage or tractional retinal 
detachment [26]. For the purpose of the analysis, patients 
with DR were classified into two groups according to the 
severity of diabetic retinopathy: mild diabetic retinopa-
thy and advanced DR (stages 3, 4 and 5 of the ETDRS 
classification).
Carotid ultrasound imaging
All the study participants underwent the same carotid 
ultrasound examination. Carotid ultrasonography imag-
ing was performed using a  LOGIQ® E9-General Electric 
(Wauwatosa, WI 53226, USA) equipped with a 15 MHz 
linear array probe or a Sequoia 512, Siemens, (North 
Rhine, Westphalia, Germany) equipped with a 15  MHz 
linear array probe. All measures and ultrasound studies 
were assessed by the same researcher at each participat-
ing hospital. The detailed carotid ultrasound protocol 
performed to evaluate the presence of carotid plaques 
has been previously described [23]. Plaques were iden-
tified using B-mode and color Doppler examinations 
in both the longitudinal and transverse planes to con-
sider circumferential asymmetry and were defined as a 
“focal structure that encroaches into the arterial lumen 
of at least 0.5  mm or 50% of the surrounding carotid 
IMT value or demonstrates a thickness of 1.5  mm, as 
measured from the media-adventitia interference to the 
intima-lumen surface” according to the Mannheim con-
sensus [27]. The arterial territories explored included the 
left and right carotid arteries; for each of them, the com-
mon and internal carotid territories and their bifurcation 
were examined.
The Local Ethics Committee of both participating cent-
ers approved the protocol, and all the participants signed 
informed consent forms.
Statistical analysis
The descriptive statistics of the mean (standard devia-
tion) or median [interquartile range] were estimated 
for quantitative variables with a normal or non-normal 
distribution, respectively. For the qualitative variables, 
absolute and relative frequencies were used. The normal 
distribution was analyzed by the Shapiro–Wilks test. The 
differences between groups were assessed by Student’s 
test, analysis of variance (ANOVA) or Mann–Whitney 
test, and Kruskal–Wallis test depending on the distribu-
tions of the quantitative variables. The significance of the 
differences in qualitative variables was assessed by Chi 
squared test or Fisher’s exact test. Logistic regression and 
multinomial logistic regression models were performed 
to study the prevalence and burden of subclinical carotid 
atherosclerotic disease and its association with DR. All 
variables of the bivariate analysis with a p < 0.2 were used. 
Only the main effects with a significant contribution to 
the final model according to the likelihood ratio test were 
included in the final model. For logistic regression model 
calibration and discrimination, the Homer–Lemeshow 
test and the area under the ROC curve were used. The 
R statistical software, version 3.3.1, was used for all the 
analyses, using a significance level of 0.05.
Sample size
Based on a predefined prevalence of DR in patients with 
type 1 diabetes of 33%, we estimated a sample size of 309 
patients with type 1 diabetes as being sufficient to detect 
a difference in the frequency of carotid atherosclerotic 
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plaques of 15% between patients with type 1 diabetes 
with and without DR, assuming frequencies of plaques of 
35 and 20% in patients with and without DR, respectively. 
This assumption yielded an overall frequency of plaques 
of 25% in this sample of subjects with type 1 diabetes. A 
comparison with a group with the same number of non-
diabetic subjects would then allow the detection of a dif-
ference of 9% between them and type 1 diabetes.
Results
From the initial number of type 1 diabetic patients 
recruited (n = 397) in the study, five patients were 
excluded for presenting an eGFR < 60  mL/min, two 
patients were excluded for presenting a urine albumin/
creatinine ratio > 300 mg/g, three patients were excluded 
for presenting cardiovascular disease and 11 patients 
were excluded for presenting with one or more oph-
thalmic exclusion criteria. Additionally, six patients did 
not attend the carotid ultrasound examination, and 30 
patients did not complete all the determinations of the 
main study outcomes. Therefore, 340 patients with type 
1 diabetes were finally enrolled in the study. We enrolled 
more subjects in the type 1 diabetes group as we allowed 
recruitment in the two centers until the control group 
was completed. A total of 332 individuals were contacted 
for inclusion in the control group. From this initial num-
ber, nine individuals did not accept participation, and 
19 were excluded because of the presence of exclusion 
criteria or for not completing all the study procedures. 
Therefore, from the expected size of the group of non-
diabetic individuals (n = 309), a total of 304 individuals 
were recruited.
Clinical variables
The results of the study variables for each study group 
are shown in Table 1. Among the 340 study patients with 
type 1 diabetes, 141 (41.5%) had DR. The patients with 
DR were older, had a higher prevalence of hypertension 
and dyslipidemia and a longer diabetes duration. These 
patients also exhibited higher systolic blood pressure, 
pulse pressure, BMI, waist circumference, plasma tri-
glycerides and HbA1c compared with those without DR 
Table 1 Clinical characteristics of the study groups
Variables are expressed as median and interquartile range, unless otherwise specified
BMI body mass index, BP blood pressure, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, Total-c total cholesterol
Control Type 1 diabetes p. control 
vs. type 1 
diabetes
p. no DR vs. 
DR
All No retinopathy Retinopathy
N = 307 N = 340 N = 199 N = 141
Age, years 44.0 [37.0; 51.0] 45.0 [37.0; 53.0] 43.4 (11.1) 48.6 (12.1) 0.164 < 0.001
Sex, men 139 (45.7%) 155 (45.6%) 89 (44.7%) 66 (46.8%) 1 0.787
Non‑caucasian 9 (2.96%) 4 (1.18%) 3 (1.51%) 1 (0.71%) 0.185 0.645
Current or former smoker 167 (55.3%) 174 (51.3%) 97 (49.0%) 77 (54.6%) 0.354 0.363
Dyslipidemia 39 (12.8%) 144 (42.4%) 72 (36.2%) 72 (51.1%) < 0.001 0.009
Hypertension 26 (8.55%) 88 (25.9%) 36 (18.1%) 52 (36.9%) < 0.001 < 0.001
Systolic BP, mmHg 120 [112; 129] 129 [114; 139] 127 [112; 135] 132 [119; 145] < 0.001 < 0.001
Diastolic BP, mmHg 76.0 [70.0; 81.0] 75.0 [68.0; 80.0] 74.5 (10.1) 73.7 (9.98) 0.009 0.447
Pulse pressure, mmHg 44.0 [38.0; 51.8] 52.0 [42.5; 62.0] 50.0 [40.0; 58.5] 56.0 [46.8; 70.0] < 0.001 < 0.001
BMI kg/m2 25.2 [23.2; 28.4] 25.6 [22.8; 28.4] 25.0 [22.5; 27.4] 26.3 [23.5; 29.4] 0.827 0.004
Waist circumference, cm 93.0 [84.2; 100] 88.0 [80.0; 98.5] 87.0 [79.0; 95.0] 90.0 [82.0; 102] < 0.001 0.003
HbA1c, % 5.40 [5.20; 5.60] 7.50 [7.00; 8.10] 7.40 [6.80; 7.90] 7.60 [7.20; 8.40] <0.001 < 0.001
HbA1c, mmol/mol 36.0 [33.0; 38.0] 58.0 [53.0; 65.0] 57.0 [51.0; 63.0] 60.0 [55.0; 68.0] < 0.001 < 0.001
Total‑c, mg/dL 192 [170; 220] 176 [160; 200] 175 [161; 200] 177 [156; 201] < 0.001 0.903
HDL, mg/dL 56.5 [47.0; 68.0] 62.0 [53.0; 74.0] 63.0 [54.0; 74.0] 60.5 [55.0; 72.8] < 0.001 0.197
LDL, mg/dL 116 [94.8; 138] 99.4 [83.0; 116] 99.4 [84.6; 116] 99.5 [79.9; 117] < 0.001 0.684
Triglycerides, mg/dL 85.0 [63.0; 122] 68.0 [53.0; 86.0] 65.0 [53.0; 83.5] 70.0 [55.0; 89.0] < 0.001 0.071
Creatinine, mg/dL 0.78 [0.68; 0.90] 0.76 [0.65; 0.87] 0.77 [0.66; 0.88] 0.76 [0.65; 0.87] 0.044 0.890
Urine albumin/creatinine ratio, 
mg/g
– 3.96 [2.08; 6.84] 3.58 [1.82; 5.95] 4.70 [2.76; 8.34] – 0.030
Diabetes duration, years – 20.0 [14.0; 29.0] 16.0 [11.0; 22.0] 27.0 [20.0; 33.0] – < 0.001
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(Table 1). The distribution of the stages of DR in the 141 
patients with DR was as follows: 89 patients had mild DR, 
18 patients had moderate DR, 15 patients had severe DR, 
and 19 patients had proliferative DR. For further analy-
sis, we classified the status of retinopathy into non-DR 
(n = 199, 58.5%), mild DR (n = 89, 26.2%), and advanced 
DR (including moderate, severe and proliferative disease) 
(n = 52, 15.3%). The clinical characteristics of these 3 
groups of patients are shown in Table 2.
Ultrasound examination
The percentage of patients with carotid plaques was 
higher in patients with type 1 diabetes compared with 
control subjects (32.6% vs. 23%, p = 0.009). The patients 
with type 1 diabetes also presented with a higher percent-
age of ≥ 2 carotid plaques (17.1% vs. 11.2%, p = 0.023) 
compared with non-diabetic subjects. In the group of 
patients with type 1 diabetes, the percentage of patients 
with carotid plaques was higher in those with DR com-
pared with those without DR (44.7% vs. 24.1%, p < 0.001). 
The patients with DR also presented a higher percentage 
of ≥ 2 carotid plaques (25.5% vs. 11.1%, p < 0.001) com-
pared to those without DR (Fig. 1).
Frequency and burden of atherosclerotic plaques 
in patients with type 1 diabetes
In the group of patients with type 1 diabetes, as the fre-
quency of subclinical carotid atherosclerosis was mainly 
at the expense of patients with advanced DR, we per-
formed a multiple regression analysis that used the group 
of patients without DR as the reference group. This anal-
ysis revealed that the variables associated with the pres-
ence of carotid plaques were age (p < 0.001), advanced DR 
(p = 0.044), smoking (p = 0.013), dyslipidemia (p < 0.001), 
pulse pressure (p = 0.014), and albumin creatinine ratio 
(p = 0.013) (Fig. 2a).
Next, we performed the multivariate logistic regres-
sion analysis for the presence of one plaque or multiple 
(≥ 2) plaques (Additional file 1: Table S1). The variables 
associated with multiple plaques were age, smoking, dys-
lipidemia, advanced stages of retinopathy, pulse pressure 
and albumin creatinine ratio (Fig. 2b).
We also performed a similar multivariate logistic 
regression analysis for the presence and absence of DR 
as a microvascular complication of atherosclerosis. In 
this analysis, we did not find a significant contribution 
of retinopathy (p = 0.140) for the presence of subclinical 
carotid atherosclerosis (Additional file 1: Table S2).
Table 2 Clinical characteristics of patients with type 1 diabetes according to the presence and severity of DR
Variables are expressed as median and interquartile range, unless otherwise specified
BMI body mass index, BP blood pressure, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, Total-c total cholesterol
No DR Mild DR > Mild DR p overall
N = 199 N = 89 N = 52
Age, years 43.4 (11.1) 47.1 (12.2) 51.1 (11.6) < 0.001
Sex, men 89 (44.7%) 41 (46.1%) 27 (51.9%) 0.906
Non‑caucasian 3 (1.51%) 1 (1.12%) 0 (0.00%) 1
Current or former smoker 97 (49.0%) 49 (55.1%) 28 (53.8%) 0.588
Antiplatelet 46 (23.1%) 23 (25.8%) 23 (44.2%) 0.009
Dyslipidemia 72 (36.2%) 41 (46.1%) 31 (59.6%) 0.007
Hypertension 36 (18.1%) 25 (28.1%) 27 (51.9%) < 0.001
Systolic BP, mmHg 127 [112; 135] 130 [119; 140] 136 [116; 150] 0.001
Diastolic BP, mmHg 74.5 (10.1) 74.4 (8.92) 72.4 (11.6) 0.395
Pulse pressure, mmHg 50.0 [40.0; 58.5] 53.0 [45.0; 66.0] 62.0 [50.5; 75.0] < 0.001
BMI, kg/m2 25.0 [22.5; 27.4] 26.2 [23.6; 29.4] 26.3 [23.3; 30.2] 0.013
Waist circumference, cm 87.0 [79.0; 95.0] 90.0 [82.0; 100] 91.5 [82.0; 103] 0.009
HbA1c, % 7.40 [6.80; 7.90] 7.50 [7.10; 8.20] 7.90 [7.30; 8.60] < 0.001
HbA1c, mmol/mol 57.0 [51.0; 63.0] 58.0 [54.0; 66.0] 63.0 [56.0; 70.0] < 0.001
Total‑c, mg/dL 175 [161; 200] 177 [154; 200] 184 [157; 201] 0.989
HDL, mg/dL 63.0 [54.0; 74.0] 60.5 [51.8; 71.0] 60.5 [50.8; 76.0] 0.422
LDL, mg/dL 99.4 [84.6; 116] 98.0 [81.8; 121] 105 [78.1; 115] 0.913
Triglycerides, mg/dL 65.0 [53.0; 83.5] 69.0 [53.0; 93.0] 74.0 [56.8; 88.0] 0.166
Creatinine, mg/dL 0.77 [0.66; 0.88] 0.75 [0.64; 0.85] 0.78 [0.68; 0.92] 0.340
Urine albumin/creatinine ratio mg/g 3.58 [1.82; 5.95] 4.00 [1.98; 5.62] 5.71 [3.12; 16.3] 0.001
Diabetes duration 16.0 [11.0; 22.0] 25.0 [18.0; 30.0] 30.5 [22.0; 38.0] < 0.001
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Frequency and burden of atherosclerotic plaques in the 
whole study group
To analyze the variables associated with the presence 
and burden of atherosclerotic plaques in the whole group 
(type 1 diabetes and non-diabetic participants), we per-
formed a logistic regression analysis. We first analyzed 
the variables associated with the presence of atheroscle-
rotic plaques. In this model, we found an interaction of 
diabetes with smoking. The variables associated with 
presence of any plaque were age (p < 0.001), dyslipidemia 
(p < 0.001), pulse pressure (p < 0.001) and smoking if type 
1 diabetes (p = 0.003) (Additional file 1: Table S3).
Next, we performed the multivariate logistic regression 
analysis for the presence of one plaque or multiple (≥ 2) 
plaques (Additional file 1: Table S3). There were several 
variables that were consistently associated with the pres-
ence of one or multiples plaques: age, dyslipidemia, pulse 
pressure and smoking if type 1 diabetes. In contrast, only 
one variable was associated with the presence of multiple 
plaques, the sex.
Discussion
In the present study, that included a large sample of 
patients with type 1 diabetes and an age- and sex-
matched control group of participants without diabetes, 
the frequency of carotid plaques was significantly higher 
in patients with type 1 diabetes. Interestingly, apart from 
other well-known cardiovascular risk factors, the pres-
ence of advanced DR was an independent predictor of 
the presence of carotid plaques and of the atherosclerotic 
burden in type 1 diabetes.
The natural history of atherosclerosis involves a pro-
tracted subclinical phase, with the atherosclerotic dis-
ease often being detected only at an advanced stage or 
after a CV event. Non-invasive methods, such as arterial 
ultrasonography, are used to detect and quantify ather-
osclerosis and have shown to be a useful screening test 
for the prediction of future CV events. It is now gener-
ally accepted that presence and burden of carotid plaques 
compared with that of carotid IMT has a higher diag-
nostic accuracy for the prediction of future CV events 
[17, 18]. Several studies showed that patients with type 1 
diabetes had a significantly increased carotid IMT com-
pared with age- and sex-matched non-diabetic subjects 
[28]. Less information is available regarding the presence 
of atherosclerotic plaques in patients with type 1 diabe-
tes, as well as its association with the presence of DR. 
In a study by Distiller et  al. in 148 patients with type 1 
diabetes (mean age 48  years, and mean diabetes dura-
tion of 26  years), the prevalence of plaques was 18.9%. 
In this study, DR was reported to be independently asso-
ciated with the presence of plaques [29]. Additionally, 
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Ogawa et al. [30] described a plaque frequency of 28.8% 
in a group of 73 patients with type 1 diabetes (mean age 
38 years) with early-onset long-duration type 1 diabetes. 
This study reported an association between prolifera-
tive DR with a maximal carotid IMT of the whole carotid 
artery. Patients with proliferative DR from that study also 
showed a non-significant higher frequency of plaques 
compared with those without this condition (42.9% vs. 
23.1%). In the current study, the presence of plaques was 
significantly higher in patients with type 1 diabetes com-
pared with non-diabetic subjects. Moreover, a higher 
proportion   of patients with type 1 diabetes presented 
with ≥ 2 carotid plaques compared with controls. The 
factors independently associated with carotid atheroscle-
rotic plaques in patients with type 1 diabetes were differ-
ent depending on whether only one plaque or ≥ 2 carotid 
plaques were present. In both cases, well-known cardio-
vascular risk factors and, more importantly, advanced 
stages of DR were independently associated with sub-
clinical atherosclerosis. Interestingly, in a recent study, 
we have reported that the frequency of preclinical carotid 
atherosclerosis in patients with latent autoimmune dia-
betes of the adults (LADA) is similar, or even greater in 
those with longer disease duration, to subjects of similar 
age with classic type 1 diabetes and type 2 diabetes [31]. 
In LADA, preclinical carotid atherosclerosis was also 
associated with classical risk factors like hypertension 
and tobacco exposure.
The data related to the presence and extent of carotid 
plaques in patients with type 2 diabetes are more abun-
dant [32]. In these patients, a high prevalence of carotid 
plaque presence and burden compared with healthy sub-
jects has been described [33]. In patients with type 2 dia-
betes, ours and other groups have previously described 
that DR is an independent risk factor associated with the 
presence of carotid plaques in subjects without previous 
0.1 1 10
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Dyslipidemia
PP, mmHg
Smoking
Urine Alb/Creat 
Mild DR
Advanced DR
OR (95% CI)
OR=2.264 (1.202 - 4.364); p=0.013
OR=1.352 (0.661 - 2.760); p=0.406
OR=1.018 (1.006 - 1.035); p=0.013
OR=1.029 (1.006 - 1.052); p=0.014
OR=3.271 (1.754 - 6.184); p<0.001
OR=1.104 (1.065 - 1.149); p<0.001
OR=2.658 (1.032 - 6.952); p=0.044
0.1 1 10 100
Age, years 
Dyslipidemia
PP, mmHg
Smoking
Urine Alb/Creat 
Mild DR
Advanced DR
OR (95% CI)
OR=1.018 (1.000 - 1.036); p=0.050
OR=4.710 (1.475 - 15.039); p=0.009
OR=1.187 (0.451 - 3.122); p=0.728
OR=2.452 (1.030 - 5.837); p=0.044
OR=1.047 (1.016 - 1.078); p=0.003
OR=2.839 (1.241 - 6.495); p=0.014
OR=1.152 (1.095 - 1.212); p<0.001
a
b
Fig. 2 Multivariate logistic regression models: a model for the presence or absence of carotid plaque in patients with type 1 diabetes. b Model for 
absence vs presence of multiple (≥ 2) plaques in patients with type 1 diabetes. Models adjusted by sex, age, diabetes duration, smoking, diastolic 
BP, dyslipidemia, diabetic retinopathy, urine albumin/creatinine ratio, BMI, pulse pressure and LDL. Smoking refers to current and former smokers
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cardiovascular disease [23, 24]. Specifically, the propor-
tion of carotid plaques in type 2 diabetes patients with 
DR was higher than in type 2 diabetes patients without 
DR; additionally, patients with DR had a higher burden 
of atherosclerosis (≥ 2 carotid plaques) [23]. Further, 
patients with type 2 diabetes and advanced stages of 
retinopathy have stenotic atherosclerotic plaques more 
frequently than patients with mild retinopathy [24].
Another proposed measure to evaluate the pres-
ence and progression of microvascular complications in 
patients with type 1 diabetes is the analysis of advanced 
glycation end-products (AGEs). In these patients, it has 
been described that accumulation of AGEs in the skin is 
independently associated with progression of retinopa-
thy as well as with presence and progression of subclini-
cal cardiovascular disease (i.e. the severity of coronary 
artery calcification and the IMT carotid progression) [34, 
35]. Other authors have suggested factors, other than 
the presence and burden of atherosclerotic plaques, that 
may be involved in the increased cardiovascular risk in 
patients with type 1 diabetes, i.e. increased arterial stiff-
ness [36, 37], and HDL dysfunction [38].
Diabetic retinopathy has been described to be associ-
ated with macrovascular disease [39], as well as with 
increased CV morbidity and mortality [7]. It is inter-
esting to note that the presence of severe DR is among 
the independent risk factors for stroke both in patients 
with type 1 diabetes [7, 22] and in patients with type 2 
diabetes [40]. Thus, the presence and extent of carotid 
atheromatous disease described in the present study in 
patients with type 1 diabetes and DR may be one of the 
factors associated with the higher risk of stroke described 
in patients with type 1 diabetes given that the presence of 
carotid plaque is an accepted independent risk factor for 
stroke. Lipid concentrations are strongly related to the 
risk of cardiovascular disease.
In patients with type 1 diabetes, it has been reported 
that in the context of good glycemic control HDL cho-
lesterol is often similar or higher, and triglycerides and 
LDL cholesterol are often lower in type 1 diabetes in 
comparison with non-diabetic subjects [41]. This is con-
sistent with the fair glycemic control observed in type 1 
diabetes patients in our study. In the current study, the 
increased HDL concentration observed in type 1 dia-
betes compared with control subjects may be related to 
the increased waist circumference in control subjects. 
The latter has already been found to be associated with 
reduced HDL concentrations in patients with type 1 dia-
betes [42].
The current study has several limitations. First, the 
study design does not allow for the identification of a 
pathophysiological link between DR and atherosclero-
sis. Additionally, the initial sample size calculation was 
primarily based on the presence of DR and not on the 
severity of this microvascular complication; given our 
findings, a larger study may be warranted to confirm the 
current results.
Conclusions
The present study performed in a large cohort of patients 
with type 1 diabetes free from CV disease shows a higher 
prevalence and burden of carotid atherosclerotic dis-
ease in these patients. In a similar way to what has been 
described in patients with type 2 diabetes, the presence 
of advanced stages of DR is independently associated 
with the presence of carotid plaques and the burden of 
atherosclerotic disease in patients with type 1 diabetes. 
Given the association described between the atheroscle-
rotic plaque burden and the risk of future CV events in 
the general population, the patients with type 1 diabe-
tes and DR may be a subgroup of patients who should 
be regarded at increased risk for future CV events and 
should be followed more closely to prevent CV disease. 
The follow-up of the whole cohort of our patients with 
type 1 diabetes may help to address these issues. The cur-
rent findings should lead to an increased awareness of DR 
as a non-classic cardiovascular risk factor for type 1 dia-
betes and to its proper consideration for preventive treat-
ment among clinicians.
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